Mizuho raised the firm’s price target on Arcutis Biotherapeutics (ARQT) to $32 from $26 and keeps an Outperform rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics price target raised to $30 from $22 at H.C. Wainwright
- Arcutis Biotherapeutics Reports Strong Q3 Earnings Call
- Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating
- Midday Fly By: OpenAI signs new Microsoft deal, PayPal reports Q3 beat
- Arcutis Biotherapeutics rises 26.5%